Lonza Biologics Inc.

Acumen Pharmaceuticals (ABOS) focuses on Alzheimer's disease treatments, targeting toxic soluble amyloid-beta oligomers (AβOs). Their lead candidate, sabirnetug (ACU193), showed positive Phase 1 results and is advancing to Phase 2. With $296.6M in cash, Acumen is well-positioned for clinical activities into 2027.

Celltrion announced the full-scale launch of its CDMO business, aiming to secure new plants by year-end and invest trillions of won in a 180,000-liter production facility. The company, with its CMO know-how and global brand power, seeks to rival Lonza and offer customized services in the pharmaceutical supply cycle.

The Biotechnology Contract Manufacturing Market is projected to grow from $16.28 Bn in 2023 to $31.05 Bn by 2031, driven by increasing demand for biopharmaceuticals, rising R&D investments, and advancements in bioprocessing technologies. Key drivers include the use of biologics in various therapeutic areas and the demand for personalized medicine. Challenges include high manufacturing costs, regulatory compliance, and intellectual property risks. Prominent players include Lonza, Samsung Biologics, and Thermo Fisher Scientific.

Lonza to manufacture CASGEVY®, the world’s first CRISPR/Cas9 gene-edited cell therapy, at its Geleen (NL) facility with plans to expand to Portsmouth, NH (US). The Geleen site is FDA, EMA, and MHRA approved for commercial production.

Casgevy, a CRISPR/Cas9-based cell therapy, offers a one-time treatment for transfusion-dependent beta-thalassemia or sickle cell disease. Lonza will manufacture Casgevy for Vertex at its Geleen (NL) facility, with plans to expand to Portsmouth (US) by 2025. Both Geleen and Portsmouth sites have received regulatory approvals.

The global Biotechnology Market is projected to reach USD 6.24 trillion by 2032, driven by R&D investments, healthcare demand, and advancements in pharmaceuticals, agriculture, and environmental management.

The report by MarketandResearch.biz analyzes the global Pharmaceutical & Biotechnology Environmental Monitoring market, focusing on growth, technological advancements, key players, and regional demand from 2015 to 2032.

Lonza's Enprotect capsule, a bi-layer enteric drug delivery solution, won the 2023 Innovation Award. Developed by a cross-functional team, it simplifies manufacturing, improves efficacy, and supports sustainability. The capsule, composed of HPMC and HPMC-AS polymers, ensures API release in the small intestine, making oral delivery viable for fragile drug modalities. Future developments aim to expand its applications, including targeted delivery in specific intestinal segments.